# Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth

> **NCT03292731** · PHASE1,PHASE2 · TERMINATED · sponsor: **Steve N. Caritis, MD** · enrollment: 159 (actual)

## Conditions studied

- Preterm Birth

## Interventions

- **DRUG:** 17-Hydroxyprogesterone caproate 250mg or 500 mg.
- **DRUG:** Safety study of 500 mg dose.

## Key facts

- **NCT ID:** NCT03292731
- **Lead sponsor:** Steve N. Caritis, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-12
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-09-02
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** grant funding cycle ended
- **Last updated:** 2023-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292731, "Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03292731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*